{"url_path":"/sec/otlk/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","accession_number":"0001104659-26-068659","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":79,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n \n \n \n\n[99.1](tm2616461d1_ex99-1.htm)\n \n[Press Release, dated June 1, 2026](tm2616461d1_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Outlook Therapeutics, Inc.**\n\n \n \n\nDate: June 1, 2026\nBy:\n/s/ Lawrence A. Kenyon\n\n \n \nLawrence A. Kenyon\n\n \n \n*Chief Financial Officer*"}